Literature DB >> 2299069

"Borderline" myocarditis: an indication for repeat endomyocardial biopsy.

G W Dec1, J T Fallon, J F Southern, I Palacios.   

Abstract

Repeat endomyocardial biopsy was performed in 28 patients with dilated cardiomyopathy of less than or equal to 12 months' duration and either symptomatic heart failure or life-threatening ventricular arrhythmias. Myocarditis was strongly suspected clinically in all cases, yet was unconfirmed on initial right ventricular biopsy. Seventeen patients underwent both right and left ventricular biopsy, seven patients had a repeat right ventricular biopsy and four patients underwent repeat left ventricular biopsy alone. The interval between initial and repeat biopsy averaged 31 +/- 6 days. Myocarditis was confirmed on repeat biopsy in 4 of 6 patients whose initial biopsy revealed "borderline" myocarditis (that is, interstitial inflammation but absence of myocyte necrosis) compared with none of the 22 patients whose initial biopsy showed either myocyte hypertrophy or interstitial fibrosis, or both (p = 0.0007). "Borderline" myocarditis on initial biopsy was the only clinical or histologic finding predictive of myocarditis on subsequent biopsy. Repeat endomyocardial biopsy can identify and potentially modify the treatment of an additional group of patients with dilated cardiomyopathy and nondiagnostic initial endomyocardial histologic features. Right ventricular sampling should be repeated in patients whose initial biopsy demonstrates "borderline" myocarditis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2299069     DOI: 10.1016/s0735-1097(10)80050-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  5 in total

1.  Diagnostic accuracy of antimyosin scintigraphy in suspected myocarditis.

Authors:  J Narula; B A Khaw; G W Dec; I F Palacios; J B Newell; J F Southern; J T Fallon; H W Strauss; E Haber; T Yasuda
Journal:  J Nucl Cardiol       Date:  1996 Sep-Oct       Impact factor: 5.952

2.  Antimyosin uptake and myofibrillarlysis in dilated cardiomyopathy.

Authors:  J Narula; J F Southern; G W Dec; I F Palacios; J B Newell; J T Fallon; H W Strauss; B A Khaw; T Yasuda
Journal:  J Nucl Cardiol       Date:  1995 Nov-Dec       Impact factor: 5.952

3.  Favorable effects of immunosuppressive therapy in children with dilated cardiomyopathy and active myocarditis.

Authors:  P R Camargo; R Snitcowsky; P L da Luz; R Mazzieri; M L Higuchi; M Rati; N Stolf; M Ebaid; F Pileggi
Journal:  Pediatr Cardiol       Date:  1995 Mar-Apr       Impact factor: 1.655

Review 4.  The spectrum of myocarditis: from pathology to the clinics.

Authors:  Ornella Leone; Maurizio Pieroni; Claudio Rapezzi; Iacopo Olivotto
Journal:  Virchows Arch       Date:  2019-07-11       Impact factor: 4.535

5. 

Authors:  F Pérez-Villa
Journal:  Medicine (Madr)       Date:  2013-04-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.